Oncotelic Therapeutics

Oncotelic Therapeutics EPS

The Earnings per Share (EPS) of Oncotelic Therapeutics (OTLC) as of Nov 19, 2026 is 0.56 USD. In the previous year, Earnings per Share (EPS) was -0.01 USD — a change of -5,170.68% (higher).

EPS

0.56USD

YoY

-5,170.68%

Last updated:

Earnings per Share (EPS) of Oncotelic Therapeutics is 2025 0.56 USD. Earnings per Share (EPS) of Oncotelic Therapeutics was 2024 -0.01 USD. It decreases by -5,170.68% higher compared to the previous year.

The Oncotelic Therapeutics EPS history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EPS
Date
EPS
Jan 1, 2018
-0.07 USD
Jan 1, 2019
-0.08 USD
Jan 1, 2020
-0.10 USD
Jan 1, 2021
-0.03 USD
Jan 1, 2022
0.01 USD
Jan 1, 2023
-0.02 USD
Jan 1, 2024
-0.01 USD
Jan 1, 2025
0.56 USD
The Oncotelic Therapeutics EPS history
YEAREPSYoY
0.56USD-5,170.68%
-0.01USD-43.90%
-0.02USD-251.98%
0.01USD-152.06%
-0.03USD-76.14%
-0.10USD+32.83%
-0.08USD+19.49%
-0.07USD-87.30%
-0.52USD+1.21%
-0.51USD-5.08%
-0.54USD-27.34%
-0.75USD-84.04%
-4.67USD-15.01%
-5.50USD-47.03%
-10.38USD-85.59%
-72.03USD-54.87%
-159.59USD-3.05%
-164.62USD-3.12%
-169.92USD+31.89%
-128.83USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Oncotelic Therapeutics Stock analysis

What does Oncotelic Therapeutics do? Oncotelic Therapeutics, Inc. develops anti-vascular therapeutics for cancer and sight-threatening eye diseases, focusing on orphan oncology indications. The company's pipeline includes OT-101, an antisense drug targeting TGF-2 for solid tumors, brain cancer in adults, and DIPG in children, as well as for treating SARS and COVID-19 viruses. CA4P, a vascular disrupting agent combined with Ipilimumab, targets melanoma in adults and pediatric cases. Oxi4503, another VDA, focuses on childhood leukemia. The company generates revenue through drug development and potential future sales of these therapeutics, targeting patients with rare cancers and viral infections. Oncotelic's products are developed for specific medical segments: OT-101 serves adult brain cancer patients and pediatric DIPG cases, while CA4P addresses melanoma in both adult and pediatric populations. Oxi4503 targets childhood leukemia, a liquid tumor condition. The company's therapeutic focus on rare and specialized conditions positions it to work with healthcare providers and potentially pharmaceutical partners for clinical trials and eventual market entry. The firm's development of antisense and small molecule injectable drugs for cancer treatment aligns with its strategy to address unmet medical needs in orphan indications. By targeting TGF-2, CA4P, and Oxi4503, Oncotelic aims to provide innovative treatments for conditions with limited therapeutic options, potentially leading to partnerships or licensing agreements for drug commercialization. Oncotelic Therapeutics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Oncotelic Therapeutics stock

Earnings per Share (EPS) of Oncotelic Therapeutics is 0.56 USD in 2025.

Earnings per Share (EPS) of Oncotelic Therapeutics changed from -0.01 USD to 0.56 USD, representing a -5,170.68% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Earnings per Share (EPS) Oncotelic Therapeutics since 2006 – with annual values, charts, and detailed analysis.

Earnings per Share measures the portion of a company's profit allocated to each outstanding share. It is a key metric for assessing a company's profitability on a per-share basis.

EPS = Net Income / Shares Outstanding

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Oncotelic Therapeutics

All Key Metrics — Oncotelic Therapeutics